Randomized controlled trialHumanClinical Trial, Phase III
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis
The New England journal of medicine, 2025 Jun 5. Sanyal AJ, Newsome PN, Kliers I and 9 others.
Study type
Randomized controlled trial · Clinical Trial, Phase III
Subjects
Human participants (PubMed MeSH: Humans)
Journal
The New England journal of medicine
Published
2025 Jun 5
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
AdultAgedFemaleHumansMaleMiddle AgedDouble-Blind MethodGlucagon-Like Peptide-1 Receptor AgonistsInjections, SubcutaneousLiverLiver CirrhosisNon-alcoholic Fatty Liver Disease
Other papers on Semaglutide
Randomized controlled trial · 2023
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Randomized controlled trial · 2021Once-Weekly Semaglutide in Adults with Overweight or Obesity
Randomized controlled trial · 2016Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page